Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Previously obtained US NDA approval and is now marketed by Sciele Pharma
Subscribe to our email newsletter
The US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for LifeCycle Pharma’s (LCP) patent application directed to its fenofibrate tablet.
The patent application covers Fenoglide, a product for which LCP has previously obtained US NDA approval and is now marketed in the US by Sciele Pharma (a Shionogi company).
William Polvino, president and CEO of LifeCycle Pharma, said: ‘This Notice of Allowance represents a strategically important accomplishment for LifeCycle Pharma and demonstrates the Company’s ability to obtain individual patents for products developed by LifeCycle Pharma that use its proprietary formulation technology.
“Our technology enables us to overcome two classic drug delivery challenges that often are in opposition, extended release and increased oral bioavailability. In addition, the technology can be implemented at commercial scale.
“The US marketing approval and new US patent Notice of Allowance validates that our innovative technology can provide patent-protected products to the market place. Upon issuance, the patent will support the ongoing sales of Fenoglide.”